Table 2.
Changes in β-gal activity and N-CAM mRNA after ampakine treatment
| Treatments | Experiment
|
Mean % increase | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |||
| In vivo | β-gal (hippocampus), % increase | 25 | 38 | 13, 2 | 33 | 1, 29, 9 | 17, 38, 10 | 20, 12, 22 | 19 ± 3* |
| N-CAM mRNA (total brain RNA), % increase | ND | ND | 28 | 63 | 21, 32, 47 | 28, 46, 3 | 8, −13, 22 | 26 ± 6† | |
| In vitro | β-gal (hippocampal slices), % increase | 58, 31, 24, 26 | 59, 3, 0 | −40, 31, 54, −2 | 77, 41, 16 | 22, 8 | 27 ± 8‡ | ||
| β-gal, % suppression by CNQX of ampakine induction | ND | ND | ND | 42, 35, 118 | 100, 150 | Mean % suppression 89 ± 22§ | |||
Changes in β-gal activity and mRNA are expressed as percentages over or under control values. For average percent increase, values are group means ± SEM. Statistics in Wilcoxon matched pairs test: ∗, P < 0.001; †, P < 0.02; ‡, P < 0.003; §, P < 0.004 by Student’s t test. Animals were killed 8 h after i.p. injection of 80 mg/kg of ampakine. β-gal assays were performed on isolated hippocampi and RNase protection assays for N-CAM mRNA were performed on total brain RNA. ND, not done.